Biomedical Engineering Reference
In-Depth Information
83. Lamprecht, A.; Ubrich, N.; Yamamoto, H.; Schäfer, U.; Takeuchi, H.; Maincent, P.;
Kawashima, Y.; Lehr, C. M. Biodegradable Nanoparticles for Targeted Drug Delivery in Treat-
ment of Inflammatory Bowel Disease.
J. Pharmacol. Exp. Ther.
2001,
299,
775-781.
84. Maeda, H. The Enhanced Permeability and Retention (EPR) Effect in Tumor Vasculature: The
Key Role of Tumor-Selective Macromolecular Drug Targeting.
Adv. Enzym. Regul.
2001,
41,
189-207.
85. Sahoo, S. K.; Sawa, T.; Fang, J.; Tanaka, S.; Miyamoto, Y.; Akaike, T.; Maeda, H. PEGylated
Zinc Protoporphyrin: A Water-Soluble Heme Oxygenase Inhibitor with Tumor-Targeting
Capacity.
Bioconjugate Chem.
2002,
13,
1031-1038.
86. Takeda, M.; Tada, H.; Higuchi, H., et al. In Vivo Single Molecular Imaging and Sentinel Node
Navigation by Nanotechnology for Molecular Targeting Drug-Delivery Systems and Tailor-
Made Medicine.
Breast Cancer
2008,
15,
145-152.
87. Cairns, R. A.; Khokha, R.; Hill, R. P. Molecular Mechanisms of Tumor Invasion and Metasta-
sis: An Integrated View.
Curr. Mol. Med.
2003,
3,
659-671.
88. Felding-Habermann, B. Integrin Adhesion Receptors in Tumor Metastasis.
Clin. Exp. Metas-
tasis
2003,
20,
203-213.
89. Lee, H. Y.; Li, Z.; Chen, K.; Hsu, A. R.; Xu, C.; Xie, J.; Sun, S.; Chen, X. ET/MRI Dual-
Modality Tumor Imaging Using Arginine Glycine-Aspartic (RGD)-Conjugated Radiolabeled
Iron Oxide Nanoparticles.
J. Nucl. Med.
2008,
49,
1371-1379.
90. Ellington, A. D.; Szostak, J. W. In Vitro Selection of RNA Molecules That Bind Specific
Ligands.
Nature
1990,
346,
818-822.
91. Tuerk, C.; Gold, L. Systematic Evolution of Ligands by Exponential Enrichment: RNA
Ligands to Bacteriophage T4 DNA Polymerase.
Science
1990,
249,
505-510.
92. Farokhzad, O. C.; Karp, J. M.; Langer, R. Nanoparticle-Aptamer Bioconjugates for Cancer
Targeting.
Exp. Opin. Drug. Del.
2006,
3,
311-324.
93. Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Wang, A. Z.; Langer, R.; Farokhzad, O. C. Nano-
technology and Aptamers: Applications in Drug Delivery.
Trends Biotechnol.
2008,
26,
442-449.
94. McCarthy, J. R.; Bhaumik, J.; Karver, M. R.; Erdem, S. S.; Weissleder, R. Review: Targeted
Nanoagents for the Detection of Cancers.
Mol. Oncol.
2010,
4,
511-528.
95. McCarthy, J. R.; Weissleder, R. Multifunctional Magnetic Nanoparticles for Targeted Imaging
and Therapy.
Adv. Drug Deliv. Rev.
2008,
60,
1241-1251.
96. Weissleder, R.; Kelly, K.; Sun, E. Y.; Shtatland, T.; Josephson, L. Cell-Specific Targeting of
Nanoparticles by Multivalent Attachment of Small Molecules.
Nat. Biotechnol.
2005,
23,
1418-1423.
97. Tassa, C.; Duffner, J. L.; Lewis, T. A.; Weissleder, R.; Schreiber, S. L.; Koehler, A. N.; Shaw,
S. Y. Binding Affinity and Kinetic Analysis of Targeted Small Molecule-Modified Nanopar-
ticles.
Bioconjug. Chem.
2010,
21,
14-19.
98. Low, P. S.; Kularatne, S. A. Folate-Targeted Therapeutic and Imaging Agents for Cancer.
Curr.
Opin. Chem. Biol.
2009,
13,
256-262.
99. Zhang, H. Y.; Ma, Y.; Sun, X. L. Recent Developments in Carbohydrate-Decorated Targeted
Drug/Gene Delivery.
Med. Res. Rev.
2010,
30,
270-289.
100. Ruenraroengsak, P.; Cook, J. M.; Florence, A. T. Nanosystem Drug Targeting: Facing up to
Complex Realities.
J. Contr. Release
2010,
141,
265-276.
101. Olivier, J. -C. Drug Transport to Brain with Targeted Nanoparticles.
NeuroRX
2005,
2,
108-119.
102. Fang, T.; Sawa, X.; Maeda, H., Eds.;
Factors and Mechanism of “EPR” Effect and the
Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS topic Series
Advances in Experimental Medicine and Biology
, SpringerLink Netherlands: Dordrecht,
Netherlands, 2004; pp 29-49.
